-

Contraline Appoints Medical Device Industry Leader Dr. Yelena Tropsha as Chief Technology Officer

  • Medical device product development and commercialization expert of 25 years, Yelena Tropsha, PhD, joins Contraline as Chief Technology Officer
  • Dr. Tropsha will spearhead efforts to bring Contraline’s male contraceptive device, ADAM, towards FDA approval

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Contraline, Inc., a venture-backed medical device company devoted to providing men with long-lasting, safe, and effective contraception has appointed medical device industry leader Dr. Yelena Tropsha to the role of Chief Technology Officer.

Dr. Tropsha brings to Contraline over 25 years of medical device experience, from front-end innovation to commercialization. Dr. Tropsha served for 10 years with Coloplast as Vice President of Implantable Devices, Urology where she was responsible for R&D, Clinical, Medical and Regulatory Affairs. Dr. Tropsha also held Vice Presidential positions with leading medical device companies DYSIS Medical and Neuronetics and senior technical positions at Medtronic and Becton Dickinson.

Over the course of her career, Dr. Tropsha has been involved in the development, approvals, and launches of 19 Class II and Class III medical devices in urology and gynecology. In addition to medical device development, her expertise is in materials science with emphasis on polymers and biomaterials. She is listed as an inventor on over 25 patents and 20 publications.

“Yelena joins our team at an exciting time ahead of our first-in-human clinical trial of ADAM™, the world’s first injectable hydrogel designed to provide long-lasting, non-permanent vas-occlusion for men,” said Kevin Eisenfrats, Co-Founder and Chief Executive Officer of Contraline.

“We are charting the path to bring a revolutionary reproductive medical device like ADAM™ to market. We are also beginning to expand the potential uses for our hydrogel platform. We will greatly benefit from Yelena’s experience leading numerous companies with innovative medical devices in urology and gynecology to successful regulatory and commercial outcomes.”

At Contraline, Dr. Tropsha will spearhead R&D, regulatory affairs, and market access. She will also lead efforts to expand use of Contraline’s proprietary hydrogel platform for new indications in reproductive health beyond vas-occlusion.

“I am excited and honored to be part of Contraline’s team, representing a new era in contraceptive technologies. Contraline’s work to develop a hydrogel for vas-occlusion draws from my areas of interest and expertise: medical device development, urology, and polymer science. The opportunity to drive the ADAM™ product from preclinical studies through commercialization will be a career highlight for me,” said Yelena Tropsha.

Dr. Tropsha holds a master’s degree in Chemistry and a PhD in Polymer Science from Moscow State University in Russia.

About Contraline

Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception. The company is developing ADAM™, the world’s first injectable hydrogel designed to provide long-lasting barrier contraception for men. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is headquartered in Charlottesville, Virginia. To learn more, visit http://www.contraline.com

Contacts

Kevin Eisenfrats
kevin@contraline.com

Contraline, Inc.


Release Versions

Contacts

Kevin Eisenfrats
kevin@contraline.com

More News From Contraline, Inc.

Contraline & Population Council Announce Option-to-License Agreement for a Revolutionary Male Contraceptive

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Contraline, Inc., a clinical-stage biotechnology company, proudly announces the signing of an exclusive option-to-license agreement with the Population Council for the Nestorone/Testosterone Transdermal Gel (NES/T) for male contraception. Upon exercising the option, Contraline will spearhead the global development and commercialization of NES/T, positioning Contraline as the world’s preeminent biotechnology company in male contraception. Contraline’s pipel...

Contraline Announces Acceptance of Abstracts to be Presented at 2023 American Urology Association and European Association of Urology Annual Meetings

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Contraline, Inc., a clinical-stage medical device company announced the acceptance of abstracts detailing the initial results from the company’s first in human clinical trial of ADAM, a hydrogel-based, long-lasting, non-hormonal, and non-permanent male contraceptive. The abstracts were written and submitted by investigators leading the study, and were accepted for presentation at the two largest, annual international urology meetings, the European Associat...

Contraline Announces First Patients Successfully Implanted in Male Contraceptive Study

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Contraline today announced the first hydrogel-based male contraceptive implants were performed in humans in a clinical trial. These procedures represent a significant milestone for the development of the company’s flagship product, ADAM, a male contraceptive that is long-lasting, non-hormonal, and non-permanent. Four men were implanted with ADAM at Epworth Freemasons Hospital in Melbourne, Australia, led by principal investigator Nathan Lawrentschuk, Profe...
Back to Newsroom